Sometimes innovation and revolution can happen in a quiet or stealthy fashion such that one may not notice until they’re in the middle of things.

Oncology R&D doesn’t stand still, it continually evolves as new and practical ideas or solutions to problems emerge, then are tested and finally (hopefully) implemented in the clinic.

The attrition rate is high, as what I call the cone of shame attests to this.

Over the ASCO weekend we saw two such examples of how change in the design of novel agents or cell therapy products can make an impact, in very different ways.

This latest post highlights one of them with two extended expert interviews and some commentary to boot…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by